OPCH Stock Forecast & Price Target

Option Care Health is well-positioned as the clear leader in home and alternate-site infusion, with about 30% market share, roughly 50 LDDs, and a broad network of 175 ambulatory infusion facilities that support scale, access, and operating leverage. Its strong balance sheet, discounted valuation versus history, and improving margin profile are reinforced by high-single-digit acute therapy growth, higher-gross-margin mix, and rising productivity as about 34% of nursing interactions now occur in ambulatory facilities, up from 17% five years ago. Although 2026 is pressured by a roughly 600-bps revenue headwind and a $55 million gross profit headwind from patient census resets, the company expects Stelara and biosimilars to represent less than 1% of revenue and gross profit in 2026, while core 2H adjusted EBITDA guidance of $237 million to $240 million implies 21%-31% core growth, supporting a constructive long-term view.

Option Care Health is facing a negative fundamental backdrop because revenue of $1.35 billion fell short of estimates and grew just 1.3% year over year, while chronic therapies declined amid Stelara-related patient census headwinds, showing that the core business is not accelerating cleanly. The outlook is further pressured by a higher-than-expected CID headwind of $55 million versus $25 million to $35 million and an aggressive implied 2H adjusted EBITDA ramp, since management would need 21% to 31% core growth without clear support from competitive exits or meaningful procurement tailwinds, which appears difficult to achieve. In addition, FY/26 guidance was cut on revenue to $5.675 billion to $5.775 billion and cash flow from operations to at least $320 million, while the company ended the quarter with only $177.3 million in cash against about $1.15 billion in debt and negative quarterly operating cash flow of $12.1 million, underscoring elevated execution and balance sheet risk.